Ulcerative Colitis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies

As per DelveInsight's assessment, globally, about 110+ key pharma and biotech companies are working on 110+ pipeline drugs in the Ulcerative Colitis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Ulcerative Colitis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ulcerative Colitis Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Ulcerative Colitis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Ulcerative Colitis Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Ulcerative Colitis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn More about the Clinical and Commercial Development Activities in the Ulcerative Colitis Therapeutics Domain:
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Ulcerative Colitis Therapeutics Analysis
There are approx. 110+ key companies which are developing the therapies for Ulcerative Colitis. Currently, Gilead Sciences is leading the therapeutics market with its Ulcerative Colitis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Ulcerative Colitis Therapeutics Market Include:
AbbVie, AbGenomics International, Abivax, Aclaris Therapeutics, Akeso Biopharma, Algernon Pharmaceuticals, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Assembly Biosciences, Athos Therapeutics, Avaxia Biologics, Bacainn Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Bristol-Myers Squibb, Celgene, Connect Biopharma, Dongwha pharma, EA Pharma, Eisai, Eli Lilly and Company, , Exeliom Biosciences SAS, Finch Therapeutics Group, First Wave Bio, Galapagos, Genentech, Giiant Pharma, GlaxoSmithKline, Gossamer Bio, Hoffmann-La Roche, Holy Stone Healthcare, Hutchison Medipharma, I-Mab Biopharma, Iltoo Pharma, Immunic, Impetis Biosciences, InDex Pharmaceuticals, Innovation Pharmaceuticals, Innovimmune Biotherapeutics, Intact Therapeutics, Intract Pharma, Istesso, Janssen Research & Development, Kaleido Biosciences, Kiniksa Pharmaceuticals, Kissei Pharma, KoBioLabs, Koutif Therapeutics, Landos Biopharma, LG Chem, Lipid Therapeutics, LTT Bio-Pharma Co Ltd, Lycera, MAKScientific, Mesoblast Ltd, Metacrine, Microbiotica, Mitsubishi Tanabe Pharma, Morphic Therapeutic, NeuClone, Novartis Pharmaceuticals, NuBiyota, NuMedii, Nyrada, Oncodesign, Oncostellae, Oppilan Pharma, OSE Immunotherapeutics, Palatin Technologies, Palobiofarma, Pandion Therapeutics, PanTheryx, ParaTech A/S, Pfizer, Pharmabiome, Pharmaxis, PNB Vesper Life Science, Progenity, Protagonist Therapeutics, Protalix BioTherapeutics, Provention Bio, PurGenesis Technologies, Qu Biologics, Rebiotix, Regentys, Reistone Biopharma, RhemaStem, Saniona, Sareum Holdings, Seres Therapeutics, Servatus, Shaperon Inc, SLA Pharma, StemRIM Inc, Sterna Biologicals, Sublimity Therapeutics Holdco, Surrozen Inc, Suzhou Connect Biopharmaceuticals, Synedgen, Synlogic Inc, Takeda Pharmaceuticals, Tarus Therapeutics, TheraSource LLC, Theravance Biopharma, Tianjin Hemay Pharmaceutical, UCB, Ventria Bioscience, VHsquared, Vivreon Biosciences, Voronoi Group, and others.

Ulcerative Colitis Emerging and Marketed Drugs Covered in the Report Include:
• Etrasimod (APD334): Arena Pharmaceuticals
• Mirikizumab (LY-3074828): Eli Lilly and Company
• Risankizumab: AbbVie
• Skyrizi (Risankizumab): AbbVie/Boehringer Ingelheim
• Stelara (Ustekinumab): Janssen Pharmaceuticals
• Remicade (Infliximab): Janssen Biotech
• Simponi (Golimumab): Janssen Pharmaceuticals
• Xeljanz (Tofacitinib): Pfizer
• Humira (Adalimumab): AbbVie
• Entyvio (Vedolizumab): Takeda Pharmaceutical
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Ulcerative Colitis Current Treatment Patterns
4. Ulcerative Colitis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ulcerative Colitis Late-Stage Products (Phase-III)
7. Ulcerative Colitis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ulcerative Colitis Discontinued Products
13. Ulcerative Colitis Product Profiles
14. Ulcerative Colitis Key Companies
15. Ulcerative Colitis Key Products
16. Dormant and Discontinued Products
17. Ulcerative Colitis Unmet Needs
18. Ulcerative Colitis Future Perspectives
19. Ulcerative Colitis Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.